Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease

G. Vurture
B. Peyronnet
A. Feigin, Zucker School of Medicine at Hofstra/Northwell
M. C. Biagioni
R. Gilbert
N. Rosenblum
Frucht
A. Di Rocco
V. W. Nitti
B. M. Brucker

Abstract

© 2018 Wiley Periodicals, Inc. Objective: To assess the safety and efficacy of intradetrusor onabotulinum toxin A injections for the treatment of overactive bladder (OAB) in patients with Parkinson's disease (PD). Methods: All PD patients who underwent intradetrusor injections of onabotulinum toxin A (BoNT-A) for storage symptoms between 2010 and 2017 were included in a retrospective study. A 100U dose of BoNT-A (Botox®, Allergan Irvine, CA) was used for the first injection in all patients. The primary endpoint was clinical success defined as any subjective improvement in OAB symptoms self-assessed by the patients 4 weeks after the injections. Results: Out of 24 patients analyzed, 19 reported improvement of their OAB symptoms 4 weeks after the first injection (79.2%) with complete resolution of urgency urinary incontinence in seven patients (29.1%; P<0.001). The average post-void residual (PVR) increased significantly after the first injection from 17.6 to 125.3mL (P<0.001). Three of the patients had to start clean intermittent catheterization (CIC) after the first injection (12.5%). Out of 49 injections in total, only five caused incomplete bladder emptying requiring the use of CIC (10.2%). Higher pre-injection PVR was significantly associated with both a lower chance of symptomatic improvement (P=0.04) and a higher risk of incomplete bladder emptying with institution of CIC (P=0.047). Conclusion: Intradetrusor injections of BoNT-A 100U appeared as a safe and effective option in PD patients with OAB symptoms and a low PVR before the injection. Higher preoperative PVR was the strongest predictor of both treatment failure and postoperative urinary retention requiring CIC.